Diagnosis and Management of Immune Related Adverse Events (irAEs)

Diagnosis and General Management

Early recognition and prompt intervention are critical to successful management of irAEs.1,2

Early involvement of multidisciplinary team: physicians, nurses, pharmacists.1,2

Exercise caution, as any new symptoms that arise may be related to irAEs.1,2

Patient and caregiver education is critical.1,2

Consult with relevant specialty services (e.g., dermatology, endocrinology) in a timely manner.1,2

Dose reductions of immune checkpoint inhibitors (ICPIs) are not recommended. Instead, permanent discontinuation or treatment interruption are recommended, as appropriate.1,2

Commonly Used Guidelines

Guidelines for Management of ICPI-associated irAEs

American Society of Clinical Oncology (ASCO)


National Comprehensive Cancer Network (NCCN®)

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Management of Immunotherapy-Related Toxicities. V.1.2021 Available at: nccn.org

The Society for Immunotherapy of Cancer (SITC)


European Society for Medical Oncology (ESMO)


Patients and Caregivers

Education

Guideline Recommendations

Provide ICPI-specific information to patients and caregivers before initiating therapy1,3

Continued patient and caregiver education throughout treatment and survivorship1

IO Wallet Card

The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient’s cancer.1 Available at: https://www.ons.org/sites/default/files/2019-01/IO%20Card%201-sided_Vertical.pdf

Patient management

KEY QUESTIONS

• Have you ever received an ICPI/immunotherapy? ✓
  • irAEs can occur after discontinuation of ICPIs3

• Do you have an immunotherapy wallet card? ✓
  • Wallet cards list the type of immunotherapy, key symptoms, and how to notify HCPs1

• Do you have an autoimmune condition? ✓
  • ICPIs may exacerbate preexisting autoimmune conditions4,5


This response is not intended to offer recommendations for administering GSK products in a manner inconsistent with approved labeling. In order for GSK to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 888-825-5249. Trademarks are property of their respective owners.